Molecular Templates

About Molecular Templates

Molecular Templates, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of targeted biologic therapeutics for cancer. Founded in 2001 and headquartered in Austin, Texas, the firm centers its research on a proprietary drug platform called Engineered Toxin Bodies (ETBs). Co-founder Eric E. Poma, who serves as CEO and Chief Scientific Officer, has been a pivotal figure since the company's inception in 2009, leading the invention of the core technology that underpins its entire clinical pipeline. His background includes a Ph.D. in Microbiology and Immunology and prior roles in business development at biotech firms like Innovive Pharmaceuticals and ImClone Systems.

The company's business model combines in-house drug development with strategic collaborations, generating revenue through licensing agreements, milestone payments, and potential royalties. Molecular Templates has established key partnerships with major pharmaceutical companies, including Takeda and Bristol Myers Squibb, to co-develop ETB-based therapies and accelerate its research. A 2017 merger with Threshold Pharmaceuticals marked its entry into the public markets.

The core of Molecular Templates' work is its ETB platform, which represents a distinct class of immunotoxins. These therapies are created by genetically fusing an antibody-based targeting domain to a de-immunized, engineered form of the Shiga-like Toxin A subunit (SLTA). This design allows ETBs to target specific cancer cells, force internalization even on receptors that do not typically internalize, and deliver a potent cell-killing payload. The mechanism of action involves the enzymatic and permanent inactivation of ribosomes, which halts protein synthesis and induces apoptosis, a process different from other approved oncology agents. This approach allows for targeting a wider range of cell surface proteins than antibody-drug conjugates (ADCs) can. The company has also developed an Antigen Seeding Technology (AST) that enables ETBs to deliver foreign viral antigens to tumor cells, marking them for destruction by the patient's immune system.

The company's clinical pipeline includes several ETB candidates in Phase I trials for various cancers. Key programs include MT-6402, which targets PD-L1 expressing tumors; MT-5111 for HER2-positive cancers; and MT-0169 for relapsed/refractory myeloma targeting CD38. These candidates are being evaluated for their potential to treat hematological malignancies and solid tumors, aiming to offer new options for patients with relapsed or refractory disease. Despite its technological promise, the company has faced financial challenges, including a delisting notification from Nasdaq in late 2024.